Zacks Small Cap Comments on Cytosorbents Co.’s FY2023 Earnings (NASDAQ:CTSO)

Cytosorbents Co. (NASDAQ:CTSO) – Stock analysts at Zacks Small Cap reduced their FY2023 EPS estimates for shares of Cytosorbents in a research note issued to investors on Tuesday, November 14th. Zacks Small Cap analyst T. Kerr now forecasts that the medical research company will post earnings of ($0.61) per share for the year, down from their previous forecast of ($0.49). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.57) per share. Zacks Small Cap also issued estimates for Cytosorbents’ Q4 2023 earnings at ($0.10) EPS, FY2024 earnings at ($0.30) EPS and FY2025 earnings at ($0.14) EPS.

A number of other research firms have also weighed in on CTSO. StockNews.com initiated coverage on shares of Cytosorbents in a research note on Thursday, October 5th. They issued a “hold” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $5.50 price objective on shares of Cytosorbents in a research report on Wednesday, August 2nd. Finally, B. Riley started coverage on shares of Cytosorbents in a report on Thursday, September 7th. They issued a “buy” rating and a $4.00 price objective for the company.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $1.17 on Thursday. The company has a market cap of $51.90 million, a P/E ratio of -2.21 and a beta of 0.79. Cytosorbents has a twelve month low of $1.03 and a twelve month high of $4.59. The company’s 50-day moving average price is $1.72 and its 200-day moving average price is $2.68. The company has a current ratio of 1.61, a quick ratio of 1.36 and a debt-to-equity ratio of 0.23.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC purchased a new stake in Cytosorbents during the second quarter worth approximately $1,149,000. Sargent Investment Group LLC boosted its holdings in shares of Cytosorbents by 23.8% in the 1st quarter. Sargent Investment Group LLC now owns 1,218,533 shares of the medical research company’s stock valued at $4,222,000 after buying an additional 234,400 shares in the last quarter. Skylands Capital LLC grew its position in shares of Cytosorbents by 8.4% in the 1st quarter. Skylands Capital LLC now owns 2,754,970 shares of the medical research company’s stock valued at $9,284,000 after buying an additional 212,879 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Cytosorbents by 129.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 298,877 shares of the medical research company’s stock worth $954,000 after acquiring an additional 168,712 shares in the last quarter. Finally, Avenir Corp lifted its position in Cytosorbents by 6.4% in the second quarter. Avenir Corp now owns 2,719,732 shares of the medical research company’s stock valued at $9,764,000 after acquiring an additional 164,179 shares during the last quarter. 34.23% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.